RELATED: Mylan, Biocon undercut insulin competitors on price with launch of Lantus copycat Bicara’s biologics engineering team is based in Bangalore, India, while its executive team is based ...

Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company have been hit with accusations of intellectual property theft.

Sept 6 (Reuters) - Bicara Therapeutics said on Friday it is seeking a valuation of up to $828 million in its initial public offering in the United States, as new listings continue to flock the ...

Morgan Stanley, TD Cowen, Cantor and Stifel acted as joint bookrunners for the offering. The gross proceeds to Bicara Therapeutics from the initial public offering, including full exercise of the ...

Sept 13 (Reuters) - Shares of Bicara Therapeutics (BCAX.O), opens new tab surged nearly 46% in their debut on Friday, giving the TPG-backed cancer therapy developer a market value of $1.29 billion ...

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today will present ...

Bicara Therapeutics presented data from an ongoing, 28-patient trial of its drug showing median overall survival of over 21 months, more than double that of Keytruda. CFO of the Year Join us for ...

Bicara Therapeutics Inc. announced multiple presentations at the AACR Annual Meeting 2025 regarding their leading therapy, ficerafusp alfa, a novel bifunctional antibody targeting EGFR and TGF-β ...

Bicara Therapeutics raised $315 million in its initial public offering in the United States, the TPG-backed cancer therapy developer said on Thursday. The company priced its offering of 17.5 million ...

Zenas BioPharma Inc. and Bicara Therapeutics Inc. on Friday both set estimated price ranges in their initial public offerings in a sign that the traditional summer lull in deals is coming to an end.

(Reuters) - Bicara Therapeutics said on Friday it is seeking a valuation of up to $828 million in its initial public offering in the United States, as new listings continue to flock the markets.